Venetoclax plus daratumumab induce hematological CR and organ response in an AL amyloidosis patient with t(11;14)

Amyloid. 2019 Sep;26(3):173-174. doi: 10.1080/13506129.2019.1615428. Epub 2019 Jun 22.

Authors

Guido Ghilardi¹, Georg Stussi¹, Luca Mazzucchelli², Christoph Röcken³, Davide Rossi¹, Bernhard Gerber¹

Affiliations

¹ a Clinic of Hematology, Oncology Institute of Southern Switzerland , Bellinzona , Switzerland.
² b Service of Clinical Cytopathology, Cantonal Institute of Pathology , Locarno , Switzerland.
³ c Department of Pathology, Christian-Albrechts-University Kiel , Kiel , Germany.

PMID: 31232114
DOI: 10.1080/13506129.2019.1615428

No abstract available

Publication types

Case Reports

MeSH terms

Aged
Antibodies, Monoclonal / therapeutic use*
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
Bridged Bicyclo Compounds, Heterocyclic / therapeutic use*
Chromosomes, Human, Pair 11
Chromosomes, Human, Pair 14
Drug Administration Schedule
Female
Humans
Immunoglobulin Light-chain Amyloidosis / drug therapy*
Immunoglobulin Light-chain Amyloidosis / genetics*
Immunoglobulin Light-chain Amyloidosis / pathology
Kidney / drug effects
Kidney / metabolism
Kidney / pathology
Myocardium / metabolism
Myocardium / pathology
Sulfonamides / therapeutic use*
Translocation, Genetic
Treatment Outcome

Substances

Antibodies, Monoclonal
Bridged Bicyclo Compounds, Heterocyclic
Sulfonamides
daratumumab
venetoclax